Antioxidants in combination therapy of men with metabolic syndrome associated with lower urinary tract symptoms and copulatory disorders

Nashivochnikova N.A., Krupin V.N., Krupin A.V., Leanovich V.E., Ibriaeva M.I.

1) Privolzhsky Research Medical University, Ministry of Health of Russia, Nizhny Novgorod, Russia; 2) Akvion JSC, Moscow, Russia

Introduction. According to epidemiological data, men with metabolic syndrome are at significantly increased risk of various diseases, including genitourinary disorders. Based on the contemporary concept of oxidative stress, excessive free radicals are considered key mediators in the pathogenesis of metabolic syndrome. Therefore, antioxidant therapy is regarded as a pathogenetically justified and therapeutically effective approach for the treatment of multiple conditions, including those in the field of urology.
Aim. To evaluate the efficiency of the dietary supplement «Querceprost» antioxidants in the combination therapy of metabolic syndrome in men associated with lower urinary tract symptoms and copulatory dysfunction.
Materials and methods. The treatment outcomes of 101 men with metabolic syndrome were analyzed. The patients were divided into two comparable groups differing only in the type of therapy received. The clinical group included 50 patients aged 45–52 years with a body mass index ≥25 kg/m2 and metabolic syndrome. In addition to standard therapy, they received the dietary supplement «Querceprost». The control group consisted of 51 patients aged 46–54 years with BMI ≥25 kg/m² and metabolic syndrome who received standard therapy only.
Outcomes were assessed at 3 and 6 months after initiation of therapy. Clinical evaluation was performed using validated questionnaires: the International Prostate Symptom Score (IPSS) and the International Index of Erectile Function (IIEF-5). Laboratory investigations included complete blood count, urinalysis, serum prostate-specific antigen (PSA), comprehensive biochemical blood analysis, total testosterone and dihydrotestosterone levels, glucose metabolism parameters (immunoreactive insulin, glucose, glycated hemoglobin), and lipid profile. Zinc concentration in seminal plasma and total antioxidant activity (TAA) of semen was measured in all patients.
All participants underwent uroflowmetry, ultrasound examination of the bladder to determine postvoid residual volume, and transrectal ultrasound of the prostate with Doppler blood flow assessment.
Results. Addition of antioxidant therapy to standard treatment in patients with metabolic syndrome significantly reduced lower urinary tract symptoms, in some cases leading to their complete resolution, as confirmed by IPSS results. The anti-inflammatory effects of the key components of the dietary supplement «Querceprost» suggest a potential influence on the pathogenetic mechanisms of benign prostatic hyperplasia progression.
Antioxidant therapy also led to improvements in erectile function in the clinical group. Patients receiving «Querceprost» demonstrated a significant increase in seminal plasma zinc concentration and positive dynamics in total antioxidant activity of the ejaculate.
Conclusions. Combination therapy of metabolic syndrome in men including antioxidant agents contributes to improvement of metabolic processes, endothelial function, and blood pressure control. This is accompanied by a statistically significant reduction in lower urinary tract symptoms and improvement of erectile function. Such therapy may influence etiopathogenetic factors in the development and progression of benign prostatic hyperplasia and may serve as an additional preventive strategy for this condition.

Keywords

About the Authors

Corresponding author: N.A. Nashivochnikova – Ph.D., Associate Professor, Department of Urology named after E.V. Shakhov, Privolzhsky Research Medical University, Ministry of Health of Russia, Nizhny Novgorod, Russia; e-mail: dom17.doctor@mail.ru

Similar Articles